Literature DB >> 31823416

Tumour-associated B cells in urothelial urinary bladder cancer.

A Ali Zirakzadeh1,2, Amir Sherif2, Robert Rosenblatt2, Emma Ahlén Bergman1, Max Winerdal1, David Yang1, Johanna Cederwall2, Vivianne Jakobsson1, Martin Hyllienmark1, Ola Winqvist3, Per Marits1.   

Abstract

Tumour infiltrating B cells and CD38+ plasma cells have been correlated with survival in different malignancies but their role in urinary bladder cancer is unclear. IL-10 is a multifunctional cytokine with both anti-inflammatory and immunostimulatory properties, that can be released by regulatory B cells (Bregs). We have stained paraffin-embedded tumour sections from 31 patients with invasive urothelial urinary bladder cancer with respect to CD20+ B cells, CD38+ cells, IL-10-expressing cells, IgG, C1q and C3a and analysed the impact of these markers on survival. Interestingly, we observe tumour-associated CD20+ B cells forming follicle-like structures in tumours of some patients. We demonstrate that follicle-like structures, tumour-associated CD38+ cells, IL-10 produced by non-B cells, tumour infiltrating IgG and activation of the complement system, may associate to longer survival of urinary bladder cancer patients. IL-10 expression by tumour-associated Bregs may instead negatively affect prognosis. More research is needed to fully understand the role of B cells and IL-10 in urinary bladder cancer.
© 2019 The Scandinavian Foundation for Immunology.

Entities:  

Keywords:  follicle-like structures; tumour-associated B cells; urinary bladder cancer

Mesh:

Substances:

Year:  2019        PMID: 31823416     DOI: 10.1111/sji.12830

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  10 in total

Review 1.  B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.

Authors:  Wolf H Fridman; Maxime Meylan; Florent Petitprez; Cheng-Ming Sun; Antoine Italiano; Catherine Sautès-Fridman
Journal:  Nat Rev Clin Oncol       Date:  2022-04-01       Impact factor: 65.011

2.  A robust 11-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts.

Authors:  Jiaxing Lin; Jieping Yang; Xiao Xu; Yutao Wang; Meng Yu; Yuyan Zhu
Journal:  Cancer Cell Int       Date:  2020-08-20       Impact factor: 5.722

3.  B cells and cancer: To B or not to B?

Authors:  Wolf Herman Fridman; Florent Petitprez; Maxime Meylan; Tom Wei-Wu Chen; Cheng-Ming Sun; Lubka T Roumenina; Catherine Sautès-Fridman
Journal:  J Exp Med       Date:  2021-01-04       Impact factor: 14.307

4.  Decreased complement 4d increases poor prognosis in patients with non-small cell lung cancer combined with gastrointestinal lymph node metastasis.

Authors:  Yan Wang; Mengqi Xiang; Huachuan Zhang; Yongda Lu
Journal:  Exp Ther Med       Date:  2022-07-05       Impact factor: 2.751

5.  Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder.

Authors:  Lennert Eismann; Severin Rodler; Alexander Buchner; Gerald Bastian Schulz; Yannic Volz; Robert Bischoff; Benedikt Ebner; Thilo Westhofen; Jozefina Casuscelli; Raphaela Waidelich; Christian Stief; Boris Schlenker; Stephan Ledderose
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

6.  Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies.

Authors:  Nicole Viveiros; Bianca Ct Flores; João Lobo; Cláudia Martins-Lima; Mariana Cantante; Paula Lopes; Cecilia Deantonio; Cintia Palu; Richard Ca Sainson; Rui Henrique; Carmen Jerónimo
Journal:  Clin Transl Immunology       Date:  2022-09-03

7.  Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer.

Authors:  Hajime Kuroda; Tsengelmaa Jamiyan; Rin Yamaguchi; Akinari Kakumoto; Akihito Abe; Oi Harada; Bayarmaa Enkhbat; Atsuko Masunaga
Journal:  Breast Cancer       Date:  2021-02-25       Impact factor: 4.239

8.  Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.

Authors:  Changhong Ke; Huan Hou; Jiayu Li; Kui Su; Chaohong Huang; Yue Lin; Zhiqiang Lu; Zhiyun Du; Wen Tan; Zhengqiang Yuan
Journal:  Cancers (Basel)       Date:  2020-05-04       Impact factor: 6.639

9.  Complement sC5b-9 and CH50 increase the risk of cancer-related mortality in patients with non-small cell lung cancer.

Authors:  Jing Li; Zhijun Cao; Lijie Mi; Zhihua Xu; Xiangmei Wu
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

Review 10.  The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures.

Authors:  Roger Li; Anders Berglund; Logan Zemp; Jasreman Dhillon; Ryan Putney; Youngchul Kim; Rohit K Jain; G Daniel Grass; José Conejo-Garcia; James J Mulé
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.